Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
AMPH Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2025 Earnings Call Transcript
Unknown11-8
The earnings call presents mixed signals. Financial performance shows increased costs and declining margins, but optimistic guidance for future growth. Product development updates are promising, especially with FDA approvals and licensing deals. Market strategy is cautious, focusing on profitability over market share. Expenses show a significant rise, impacting financial health. Shareholder returns are slightly positive with buybacks. The Q&A indicates stable future growth, but management's vague responses about timelines and competition raise concerns. Considering the mid-sized market cap, the stock is likely to experience a neutral reaction, with potential for slight fluctuations.
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call presents a mixed picture: strong BAQSIMI sales growth and strategic partnerships are positives, but flat revenue guidance, declining margins, and competitive pressures in several product lines pose challenges. The Q&A session reveals management's cautious optimism but also highlights uncertainties, especially regarding AMP-002 approval and competitive pressures. The market cap suggests moderate reaction to these factors, leading to a neutral stock price prediction.
Earnings call transcript: Amphastar Q1 2025 misses earnings, stock edges up
Unknown5-7
The earnings call reveals several negative factors: declining net income and gross margins, increased competition affecting key product sales, and vague management responses in the Q&A. While there is a strategic partnership and a share buyback program, the weak guidance, increased competition, and margin pressures outweigh these positives. The market cap suggests a moderate reaction, leading to a 'negative' prediction for stock price movement.
AMPH Slides
AMPH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
